233 related articles for article (PubMed ID: 29336935)
1. Update on the laboratory investigation of dyslipidemias.
Ramasamy I
Clin Chim Acta; 2018 Apr; 479():103-125. PubMed ID: 29336935
[TBL] [Abstract][Full Text] [Related]
2. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia.
Oravec S; Dostal E; Dukát A; Gavorník P; Kucera M; Gruber K
Neuro Endocrinol Lett; 2011; 32(4):502-9. PubMed ID: 21876506
[TBL] [Abstract][Full Text] [Related]
3. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment.
Carr SS; Hooper AJ; Sullivan DR; Burnett JR
Pathology; 2019 Feb; 51(2):148-154. PubMed ID: 30595507
[TBL] [Abstract][Full Text] [Related]
4. Sugar-Sweetened Beverage Consumption and Plasma Lipoprotein Cholesterol, Apolipoprotein, and Lipoprotein Particle Size Concentrations in US Adults.
Haslam DE; Chasman DI; Peloso GM; Herman MA; Dupuis J; Lichtenstein AH; Smith CE; Ridker PM; Jacques PF; Mora S; McKeown NM
J Nutr; 2022 Nov; 152(11):2534-2545. PubMed ID: 36774119
[TBL] [Abstract][Full Text] [Related]
5. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
6. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.
Lawler PR; Akinkuolie AO; Chu AY; Shah SH; Kraus WE; Craig D; Padmanabhan L; Glynn RJ; Ridker PM; Chasman DI; Mora S
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28733430
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and management of familial dyslipoproteinemias.
Kwiterovich PO
Curr Cardiol Rep; 2013 Jun; 15(6):371. PubMed ID: 23666884
[TBL] [Abstract][Full Text] [Related]
8. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
[TBL] [Abstract][Full Text] [Related]
9. Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? New Insights From the Framingham Offspring Study.
Bartlett J; Predazzi IM; Williams SM; Bush WS; Kim Y; Havas S; Toth PP; Fazio S; Miller M
Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):206-212. PubMed ID: 27166203
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes.
Berneis K; Jeanneret C; Muser J; Felix B; Miserez AR
Metabolism; 2005 Feb; 54(2):227-34. PubMed ID: 15690318
[TBL] [Abstract][Full Text] [Related]
11. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men.
Lamarche B; St-Pierre AC; Ruel IL; Cantin B; Dagenais GR; Després JP
Can J Cardiol; 2001 Aug; 17(8):859-65. PubMed ID: 11521128
[TBL] [Abstract][Full Text] [Related]
12. Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement.
Contois JH; Warnick GR; Sniderman AD
J Clin Lipidol; 2011; 5(4):264-72. PubMed ID: 21784371
[TBL] [Abstract][Full Text] [Related]
13. ApoB versus non-HDL-cholesterol: diagnosis and cardiovascular risk management.
de Nijs T; Sniderman A; de Graaf J
Crit Rev Clin Lab Sci; 2013 Nov; 50(6):163-71. PubMed ID: 24295059
[TBL] [Abstract][Full Text] [Related]
14. High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk.
Hafiane A; Genest J
BBA Clin; 2015 Jun; 3():175-88. PubMed ID: 26674734
[TBL] [Abstract][Full Text] [Related]
15. NMR analysis of lipoprotein particle size does not increase sensitivity to the effect of soy protein on CVD risk when compared with the traditional lipid profile.
Santo AS; Cunningham AM; Alhassan S; Browne RW; Burton H; Leddy JJ; Grandjean PW; Horvath SM; Horvath PJ
Appl Physiol Nutr Metab; 2008 Jun; 33(3):489-500. PubMed ID: 18461102
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial).
Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
Am J Cardiol; 2011 Jul; 108(1):40-6. PubMed ID: 21565322
[TBL] [Abstract][Full Text] [Related]
17. Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis.
Forte TM; Nichols AV; Krauss RM; Norum RA
J Clin Invest; 1984 Nov; 74(5):1601-13. PubMed ID: 6501564
[TBL] [Abstract][Full Text] [Related]
18. An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB.
Sniderman AD; Toth PP; Thanassoulis G; Furberg CD
J Clin Lipidol; 2016; 10(5):1248-58. PubMed ID: 27678443
[TBL] [Abstract][Full Text] [Related]
19. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
